COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma
COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma
Safety follow-up of the randomized, phase 3 study DESTINY-Breast03
Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer
An AI-derived digital pathology-based biomarker to predict the benefit of ADT in PC with validation in NRG/RTOG 9408
The optimal approach after neoadjuvant treatment: The Lucerne toolbox
OncoAlert Colloquium Day 6: Gynaecological oncology, IGCS and ESO
OncoAlert Colloquium Day 5: SWOG, OncoAlliance and more
OncoAlert Colloquium Day 4: GI oncology and EONS
OncoAlert Colloquium Day 3: Breast cancer
OncoAlert Colloquium Day 2: Lung cancer and MASCC
OncoAlert Colloquium Day 1: Genitourinary cancers and geriatric oncology
The RxPONDER trial and its impact on best clinical practice